Hamivand Zari, Haddadi Gholamhassan, Fardid Reza
Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Ionizing and Non-Ionizing Radiation Protection Research Center (INIRPRC), Shiraz University of Medical Sciences, Shiraz.
J Med Phys. 2018 Jan-Mar;43(1):41-45. doi: 10.4103/jmp.JMP_104_17.
Thyroid cancer is the most common endocrine malignancy worldwide. Iodine-131 is used in the treatment of thyroid cancer with dosage of 100 mCi. In the medical applications of ionizing radiation besides the advantages such as diagnosis and treatment of diseases, the risks arising from exposure should be considered as well.
The present study aimed to evaluate the changes in expression levels of apoptotic Bax and Bcl-2 and the ratio of Bax/Bcl-2, in the peripheral blood lymphocytes (PBLs) of patients with differentiated thyroid cancer (DTC).
This study was conducted on fifty thyroid cancer patients who had undergone surgery and were under treatment with 100 and 150 mCi doses. Subjects and Methods: Blood samples were taken from the patients, one before iodine treatment and another 48 h after therapy. Bax and Bcl-2 gene expression levels were measured by using real-time reverse transcriptase polymerase chain reaction.
The data were analyzed using one-way analysis of variance followed by samples -test and independent samples -test.
Significant changes were observed in the percentage of apoptotic cells, in groups, after radioiodine therapy compared with before treatment. The ratio of Bax/Bcl-2 in both groups showed a significant increase ( < 0.001). The relative expression level of Bax gene showed a significant increase in comparison with the control group.
Iodine therapy reduced expression of Bcl-2 and a significant expression of Bax and finally increased the ratio of Bax/Bcl-2. Iodine therapy led to apoptosis in the PBLs of patients with DTC. Therefore, it can be suggested that this method can be useful for monitoring and detecting destructive effects of ionizing radiation in nuclear medicine patients.
甲状腺癌是全球最常见的内分泌恶性肿瘤。碘 - 131用于治疗甲状腺癌，剂量为100毫居里。在电离辐射的医学应用中，除了疾病诊断和治疗等优点外，还应考虑暴露所带来的风险。
本研究旨在评估分化型甲状腺癌（DTC）患者外周血淋巴细胞（PBLs）中凋亡相关蛋白Bax和Bcl - 2的表达水平变化以及Bax/Bcl - 2比值。
本研究对50例接受过手术且正在接受100和150毫居里剂量治疗的甲状腺癌患者进行。对象与方法：采集患者血液样本，一份在碘治疗前，另一份在治疗后48小时。使用实时逆转录聚合酶链反应测量Bax和Bcl - 2基因表达水平。
数据采用单因素方差分析，随后进行样本检验和独立样本检验。
与治疗前相比，放射性碘治疗后各组凋亡细胞百分比有显著变化。两组的Bax/Bcl - 2比值均显著升高（P < 0.001）。与对照组相比，Bax基因的相对表达水平显著升高。
碘治疗降低了Bcl - 2的表达，显著增加了Bax的表达，最终提高了Bax/Bcl - 2比值。碘治疗导致DTC患者的PBLs发生凋亡。因此，可以认为该方法有助于监测和检测核医学患者中电离辐射的破坏作用。
